UCSF

Tagged: drug discovery and development

SARS-CoV-2 may spur growth of molecular “railways” out of infected cells, School scientists show

UCSF-led collaboration uncovers new avenues for COVID-19 drug discovery

QBI Coronavirus Research Group identifies drugs that block SARS-CoV-2 in the laboratory

The QBI Coronavirus Research Group found six drugs that effectively beat back SARS-COV-2 in the laboratory.

In clinical work and discovery science, the School takes on COVID-19

The UCSF School of Pharmacy is moving quickly against the COVID-19 pandemic, applying a scientific mindset to challenges being raised during the crisis.

Arkin receives Ono Pharma Foundation Breakthrough Science Initiative Award

Michelle Arkin, PhD, has received the 2018 Breakthrough Science Initiative Award from the Ono Pharma Foundation to study a class of proteins, called 14-3-3 proteins, known to be involved in various cancers, with the ultimate goal of enabling discoveries that lead to new ways to treat cancer.

UCSF School of Pharmacy joins data-sharing partnership to speed cancer drugs

A pioneering public/private consortium is poised to turn the marathon of drug discovery into a team relay, maybe even a short one.

Computer models speed UCSF scientists toward psychiatric drug discoveries

For decades, scientists have wanted to be able to study dopamine receptors one by one. The brain’s dopamine receptors are responsible for a variety of behaviors, such as reward seeking, and are also involved in psychiatric illnesses like schizophrenia.

Jacobson named chair of the Department of Pharmaceutical Chemistry

Renowned researcher and educator Matthew Jacobson, PhD, has been named the new chair of the UCSF School of Pharmacy’s Department of Pharmaceutical Chemistry. His appointment by Dean B. Joseph Guglielmo, PharmD, will be effective January 15, 2016.

Computer models successfully predict drug side effects

New computer models were able to successfully predict negative side effects for hundreds of currently marketed drugs, report researchers from the UCSF School of Pharmacy, SeaChange Pharmaceuticals, and Novartis Institutes for Biomedical Research in

Fischbach receives Packard Fellowship

Michael Fischbach, PhD, who studies drug-like molecules produced by human gut bacteria, has been awarded one the 16 prestigious 2011 Packard Fellowships in Science and Engineering.

Giacomini cites increasing impact of quantitative pharmacology

Pharmaceutical companies will increasingly apply the predictive modeling of quantitative pharmacology to do more efficient drug development, says Kathy Giacomini, PhD, co-chair of the Department of Bioengineering and Therapeutic Sciences (BTS), a joint department

Pages